Skip to main content

Genomas, Partners Share SBIR Grant for DNA-Guided Therapy Management System

NEW YORK (GenomeWeb News) – Genomas, along with partners from Hartford Hospital, the Rogosin Institute, and the University of California San Francisco, will use a $1.2 million Small Business Innovation Research grant to develop DNA-guided clinical management systems to predict and compare an individual's risk of certain adverse reactions to statin medications, the company said Wednesday.
 
Statins are among the most popularly prescribed drugs in the world, but also have adverse nerve and muscle-related side effects such as aches, cramps, weakness, and injury that disable 10 percent of the patients and require therapeutic changes.
 
The research that led to the award was conducted by Hartford Hospital and UCSF and was published in the September 2007 journal Muscle & Nerve.
 
The Hartford, Conn.-based company will integrate the knowledge of Hartford Hospital with its physiogenomics technology to develop the PhyzioType Clinical Management System, which will include a group of inherited DNA markers genotyped by arrays and interpreted by an algorithm. The system will help doctors predict and compare the risk of side effects for individual patients, the company said.
 
Genomas noted that to date it has received $3.1 million in NIH SBIR funding to develop the PhyzioType.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.